Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CRHBP | P24387 | 2/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343091 | 1.00 | ITGB2 (0.38) | ITGB2ICAM1ITGALADRA2AADRA2C | |
| SCHEMBL5248739 | 0.77 | ITGB2 (0.38) | ITGB2ICAM1ITGALADRA2AADRA2C | |
| SCHEMBL20756201 | 0.77 | ADRA2A (0.40) | ITGB2ICAM1ITGALADRA2AADRA2C | |
| SCHEMBL3115776 | 0.77 | ALDH1A1 (0.44) | ITGB2ICAM1ITGALADRA2AADRA2C | |
| SCHEMBL30641376 | 0.77 | ADRA2A (0.40) | ITGB2ICAM1ITGALADRA2AADRA2C | |
| SCHEMBL16404623 | 0.77 | MAPT (0.43) | ITGB2ICAM1ITGALADRA2AADRA2C | |
| SCHEMBL15202099 | 0.77 | FABP6 (0.40) | ITGB2ICAM1ITGALADRA2AADRA2C | |
| SCHEMBL2085452 | 0.77 | PARP1 (0.44) | ALDH1A1HSD17B10GAAMAPTLMNA | |
| SCHEMBL16931646 | 0.76 | ADRA2A (0.52) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL12714478 | 0.75 | FABP6 (0.43) | ITGB2ICAM1ITGALALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1428514-B1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, a tertiary paraphenylenediamine and a benzomorpholine coupler; method and use | OREAL (FR) | 2007-09-19 | — | — | EP | claimed |
| US-20040205903-A1 | Dyeing composition comprising a cationic pyrrolidine-based para-phenylenefiamine, a tertiary para-phenylenediamine and a benzomorpholine coupler, methods and uses | L'OREAL (FR) | 2004-10-21 | — | — | US | claimed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12503447-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| WO-2024259303-A1 | COMPOUNDS AND COMPOSITIONS AS CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4071140-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4071140-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-113896744-B | Selective EGFR inhibitor | 成都先导药物开发股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-113929618-B | Oxo-pyridine amide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-113912586-B | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20040205903-A1 | Dyeing composition comprising a cationic pyrrolidine-based para-phenylenefiamine, a tertiary para-phenylenediamine and a benzomorpholine coupler, methods and uses | L'OREAL (FR) | 2004-10-21 | — | — | US | disclosed |
| EP-0705835-A1 | Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040205903-A1 | Dyeing composition comprising a cationic pyrrolidine-based para-phenylenefiamine, a tertiary para-phenylenediamine and a benzomorpholine coupler, methods and uses | CDC73, KRT18, PAH | ITGB2 4728/4885ICAM1 4084/4885ITGAL 4517/4885 |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | ITGB2 3278/4885ICAM1 1459/4885ITGAL 3795/4885 |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | ITGB2 3156/4885ICAM1 4036/4885ITGAL 3423/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | ITGB2 3156/4885ICAM1 4036/4885ITGAL 3423/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | ITGB2 1723/4885ICAM1 1262/4885ITGAL 3404/4885 |
| US-12503447-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | ITGB2 1886/4885ICAM1 3729/4885ITGAL 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.